Drug-eluting Balloon Catheters Market By Product Type (Paclitaxel Drug-Eluting Balloon Catheters, Sirolimus Drug-Eluting Balloon Catheters) , By Indication (Coronary Intervention, Peripheral Intervention) By End User (Hospitals and ASCs, Catheterization Laboratories, Others) : Global Opportunity Analysis and Industry Forecast, 2024-2033
The drug-eluting balloon catheters market was valued at $0.6 billion in 2023, and is projected to reach $1.5 billion by 2033, growing at a CAGR of 8.7% from 2024 to 2033.
Drug-eluting balloon catheters are specialized medical devices used in interventional cardiology and vascular procedures. These catheters are coated with medication that is released into the target tissue during the balloon inflation process. This technology aims to prevent restenosis (re-narrowing of blood vessels) after procedures such as angioplasty, where a balloon is used to open up blocked arteries.
The growth of the global drug-eluting balloon catheters market is majorly driven by alarming rise in prevalence of cardiovascular diseases such as coronary artery disease and peripheral artery disease. According to a 2023 study of the World Heart Federation, deaths due to cardiovascular disease increased from 12.1 million in 1990 to 20.5 million in 2021. In addition, surge in geriatric population significantly contributes toward the growth of the global market. This is attributed to the fact that as individuals age, their bodies undergo natural physiological changes such as arterial stiffness, reduced elasticity of blood vessels, and changes in heart structure and function, which can contribute to conditions like hypertension and heart disease. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050. Moreover, shift toward minimally invasive surgical techniques among healthcare providers and patients leads to higher demand for drug-eluting balloons, thereby augmenting the market growth. Furthermore, increase in investments in healthcare infrastructure and growing spending on advanced medical devices contribute to the market expansion. However, high cost associated with drug-eluting balloon catheters hampers the market growth. In addition, availability of other treatment options, such as drug-eluting stents or traditional surgical procedures, can create competitive pressures and limit the market share for drug-eluting balloon catheters. On the contrary, continuous innovations in catheter design and drug formulation improve the effectiveness and safety profiles of drug-eluting balloon catheters, which are expected to offer lucrative opportunities for the growth of the global market during the forecast period.
The global drug-eluting balloon catheters market size is segmented into product type, indication, end user, and region. By product type, the market is bifurcated into paclitaxel drug-eluting balloon catheters and sirolimus drug-eluting balloon catheters. On the basis of indication, it is classified into coronary intervention and peripheral intervention. Depending on end user, it is fragmented into hospitals and ASCs, catheterization laboratories, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key FindingsBy product type, the paclitaxel drug-eluting balloon catheters segment is expected to dominate the market from 2024 to 2033.On the basis of indication, the peripheral intervention segment is anticipated to exhibit the highest growth during the forecast period.
Depending on end user, hospital segment is likely to grow at a notable pace in the coming years.
Region wise, North America is projected to emerge as the most lucrative market for drug-eluting balloon catheters throughout the forecast period.
Competition AnalysisCompetitive analysis and profiles of the major players in the global drug-eluting balloon catheters market include Medtronic, Koninklijke Philips N.V., Becton, Dickinson and Company, Lepu Medical Technology(Beijing)Co.,Ltd., Meril Life Sciences Pvt. Ltd., Biotronik, Zhejiang Barty Medical Technology Co., Ltd., Eurocor Tech GmbH, iVascular, and Concept Medical. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.
Key Market SegmentsBy Product TypePaclitaxel Drug-Eluting Balloon Catheters
Sirolimus Drug-Eluting Balloon Catheters
By IndicationCoronary Intervention
Peripheral Intervention
By End UserHospitals and ASCs
Catheterization Laboratories
Others
By RegionNorth America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market PlayersMedtronic
Koninklijke Philips N.V.
Becton, Dickinson and Company
Lepu Medical Technology(Beijing)Co.,Ltd.
Meril Life Sciences Pvt. Ltd.
Biotronik
Zhejiang Barty Medical Technology Co., Ltd.
Eurocor Tech GmbH
iVascular
Concept Medical